Alpha 2.0
Login Register
» Authors » Normann Steiner

Normann Steiner

Explore the profile of Normann Steiner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 276
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
Eberhard Gunsilius
Wolfgang Willenbacher
Dominik Wolf
David Nachbaur
Georg Gobel
Gerold Untergasser
Karin Johrer
Bojana Borjan
Johann Kern
Michael Mian
Published In
Cancers (Basel)
Oncotarget
Anticancer Res
Ann Hematol
Transplant Cell Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis
Ahmad O, Kroger N, Wagner-Drouet E, Nachbaur D, Steiner N, Teschner D, et al.
Bone Marrow Transplant . 2025 Mar; PMID: 40074786
No abstract available.
2.
Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted Agents
Bohn J, Stolzlechner V, Gobel G, Willenbacher W, Pirklbauer M, Steiner N, et al.
Cancers (Basel) . 2024 Nov; 16(22). PMID: 39594701
: Elevated beta-2-microglobulin (B2M) plasma levels commonly imply a higher CLL-IPI risk category for short overall survival (OS), but the risk model was not adjusted for compromised kidney function and...
3.
Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients
Massoud R, Klyuchnikov E, Steiner N, Zeck G, Heidenreich S, Langebrake C, et al.
Transplant Cell Ther . 2024 Oct; 31(1):20.e1-20.e14. PMID: 39419178
As with myelodysplastic syndromes (MDS), effective treatment options for chronic myelomonocytic leukemia (CMML) are limited, and the optimal treatment approach remains undefined. Allogeneic stem cell transplantation (allo-SCT) is potentially curative...
4.
Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission
Steiner N, Massoud R, Richter J, Perekhrestenko T, Gagelmann N, Niederwieser C, et al.
Eur J Haematol . 2024 Sep; 114(1):79-88. PMID: 39300830
Background: The optimal TBI dose for ALL patients undergoing allogeneic SCT is still not clearly defined. Methods: Single-center retrospective analysis of high-risk ALL patients in CR1 treated with 8 Gy...
5.
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function
Bohn J, Stolzlechner V, Gobel G, Pirklbauer M, Wolf D, Steiner N
Leuk Lymphoma . 2024 Aug; 65(14):2108-2115. PMID: 39165182
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and characterized by a highly heterogeneous clinical course. The CLL-IPI and the OCLL-1 scores are among the best validated...
6.
Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation
Steiner N, Massoud R, Klyuchnikov E, Gagelmann N, Richter J, Niederwieser C, et al.
Bone Marrow Transplant . 2024 Jun; 59(9):1265-1274. PMID: 38877098
We retrospectively analyzed high-risk ALL patients in CR1 receiving total body irradiation based conditioning regimen with ATLG (n = 74) or PTCy (n = 73) for GVHD prophylaxis. The 3-year...
7.
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies
Reimann P, Petzer V, Mundlein A, Hartmann B, Severgnini L, Winkler A, et al.
Ann Hematol . 2024 Mar; 103(6):2123-2131. PMID: 38436671
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in...
8.
Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
Steiner N, Gobel G, Mauser L, Muhlnikel L, Fischinger M, Kunz T, et al.
Cancers (Basel) . 2023 Feb; 15(3). PMID: 36765566
In our single-center study, 357 myeloma and lymphoma patients between 2009 and 2019 were mobilized with granulocyte colony-stimulating factor (G-CSF 7.5 µg/kg bid for four days) plus a fixed dose...
9.
Autologous and Allogeneic Stem Cell Transplantation as Salvage Treatment Options for Relapsed/Refractory Multiple Myeloma: A Single-center Experience over 20 Years
Steiner N, Schober P, Willenbacher W, Kircher B, Gunsilius E, Wolf D, et al.
Anticancer Res . 2022 Dec; 42(12):5825-5832. PMID: 36456157
Background/aim: Despite multiple treatment options, multiple myeloma (MM) remains an incurable disease with poor outcome. Patients And Methods: We retrospectively analyzed the outcome of MM patients undergoing an allogeneic (allo-SCT;...
10.
Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
Locher M, Jukic E, Vogi V, Keller M, Kroll T, Schwendinger S, et al.
Eur J Haematol . 2022 Nov; 110(3):296-304. PMID: 36433728
Long-term disease control in multiple myeloma (MM) is typically an unmet medical need, and most patients experience multiple relapses. Fluorescence in situ hybridization (FISH) is the standard technique to detect...